Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Total Liabilities (2017 - 2025)

Inmune Bio (INMB) has disclosed Total Liabilities for 9 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 18.25% to $8.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.8 million through Dec 2025, up 18.25% year-over-year, with the annual reading at $8.8 million for FY2025, 18.25% up from the prior year.
  • Total Liabilities hit $8.8 million in Q4 2025 for Inmune Bio, up from $8.0 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $21.7 million in Q4 2022 to a low of $2.3 million in Q1 2021.
  • Historically, Total Liabilities has averaged $15.0 million across 5 years, with a median of $17.8 million in 2022.
  • Biggest five-year swings in Total Liabilities: surged 1181.82% in 2021 and later crashed 60.42% in 2024.
  • Year by year, Total Liabilities stood at $19.7 million in 2021, then increased by 9.99% to $21.7 million in 2022, then decreased by 13.04% to $18.9 million in 2023, then plummeted by 60.42% to $7.5 million in 2024, then rose by 18.25% to $8.8 million in 2025.
  • Business Quant data shows Total Liabilities for INMB at $8.8 million in Q4 2025, $8.0 million in Q3 2025, and $8.8 million in Q2 2025.